Tecovirimat

From IDWiki

Background

  • Antiviral indicated for smallpox but used off-label for severe mpox as well
  • For mpox, guidance in Ontario limits it to patients who are severely ill or disabled from mpox, or who are at high risk of progression to severe disease
    • Hospitalized patients with severe disease (e.g., hemorrhagic disease, sepsis, encephalitis, myocarditis, esophagitis, or other conditions requiring hospitalization)
    • Persons who may be at high risk of severe disease:
      • Persons who are severely immunocompromised (e.g., individuals with HIV with current CD4 counts < 200/mm3 or with uncontrolled viral loads; receiving active treatment for solid tumour or hematologic malignancies such as chemotherapy, targeted therapies, or immunotherapy; recipients of solid-organ transplant and taking immunosuppressive therapy; recipients of hematopoietic stem cell transplant within 2 years of transplantation or taking immunosuppression therapy; autoimmune with immunodeficiency as a clinical component; on treatment with agents such as tumor necrosis factor or high-dose corticosteroids);
      • Pediatric populations, particularly patients younger than 10 years of age (see Table 2);
      • Pregnant or breastfeeding women
      • Persons with one or more complications (e.g., severe secondary bacterial skin infection; gastroenteritis with severe nausea/vomiting, diarrhea, or dehydration; bronchopneumonia; concurrent disease or other comorbidities).
    • Persons with mpox virus infections with lesions that are leading to significant disability (e.g., proctitis, keratitis or other ocular involvement, pharyngitis/epiglottitis or other breathing/swallowing compromise).

Dosing

  • 13 to ≤25 kg: 200 mg p.o. twice daily for 14 days
  • 25 to ≤40 kg: 400 mg p.o. twice daily for 14 days
  • ≥40 kg: 600 mg p.o. twice daily for 14 days

Safety

Adverse Effects

  • Most common were headache, nausea, abdominal pain, and vomiting
  • Gastrointestinal: dry mouth, chapped lips, dyspepsia, eructation, and oral paresthesia.
  • General pyrexia, pain, chills, malaise, and thirst.
  • Investigations: abnormal electroencephalogram, hematocrit decreased, hemoglobin decreased, heart rate increased and QTc prolongation.
  • Musculoskeletal and connective tissue: arthralgia and osteoarthritis.
  • Nervous system: migraine, disturbance in attention, dysgeusia and paresthesia.
  • Psychiatric: depression, dysphoria, irritability, and panic attack.
  • Respiratory, Thoracic and Mediastinal Disorders: oropharyngeal pain.
  • Skin and subcutaneous tissue: palpable purpura, rash, pruritic rash, facial redness, facial swelling, and pruritus